Magnetic resonance imaging (MRI) has emerged as a leading diagnostic technique in clinical and preclinical settings. However, the application of MRI to assess specific disease markers for diagnosis and monitoring drug effect has been severely hampered by the lack of desired contrast agents with high relaxivities, and optimized in vivo retention time. We have reported the development of protein-based MRI contrast agents (ProCA1) by rational design of Gd 3+ binding sites into a stable protein resulting in significantly increased longitudinal (r 1 ) and transverse (r 2 ) relaxivities compared to Gd-DTPA. Here, we report a further improvement of protein contrast agents ProCA1 for in vivo imaging by protein modification with various sizes of polyethylene glycol (PEG) chain. PEGylation results in significant increases of both r 1 and r 2 relaxivities (up to 200%), and these high relaxivities persist even at field strengths up to 9.4 T. In addition, our experimental results demonstrate that modified contrast agents have significant improvement of in vivo MR imaging and biocompatibilities including dose efficiency, protein solubility, blood retention time and decreased immunogenicity. Such improvement can be important to the animal imaging and pre-clinical research at high or ultra-high field where there is an urgent need for molecular imaging probes and optimized contrast agent.
Introduction
Magnetic resonance imaging (MRI) has unique advantages in capturing 3-dimensional images of living systems with high spatial resolution and without limitations of the depth of tissue/organs and ionized radiation [1] [2] [3] [4] [5] . MRI has emerged as a leading diagnostic technique in clinical and preclinical settings [6, 7] . In addition, it allows for non-invasive and repetitive assessment of biological processes with the same living subject at different time points, which significantly reduces both the number of animals required and cost [8] [9] [10] . However, the application of MRI to assess specific disease markers for diagnosis and monitoring drug effects has been severely hampered by the lack of desired contrast agents with high relaxivity, minimal or no toxicity, and optimized in vivo retention time [11] . For example, gadolinium-diethylenetriamine pentaacetic acid (Gd-DPTA), a current clinically approved MRI contrast agent, has a low relaxivity value of ~5 mM −1 s −1 and requires an injection dose of up to 0.1 mmol kg −1 body weight for clinical application in animals and humans [12] . In addition, Gd-DPTA may not be suitable for some advanced in vivo MRI applications due to a high glomerular filtration rate for this small chelate molecule [13, 14] . The non-covalent binding of small chelate to plasma proteins, such as albumin (MS-325), greatly increases the relaxivity with a good MR angiography [15, 16] . There is a strong need to develop MRI contrast agents with improved relaxivity, optimized pharmacokinetics, and application to molecular imaging.
We have reported the development of protein-based MRI contrast agents (ProCA1, previously named as CA1.CD2) by rational design of Gd 3+ binding sites into a stable protein using amino acid residues as metal coordinating ligands [17] . Our specially designed Gdbinding protein-based contrast agents are different from other reported macromolecular MRI contrast agents, such as Gd-DTPA-based dendrimers, or nano-sized contrast agents that are developed by multiple attachment of an existing small chelator for Gd 3+ . Our designed protein MRI contrast agent exhibits higher r 1 and r 2 relaxivities compared to Gd-DTPA. Here, we report a further improvement in the design of protein based contrast agents ProCA1 for in vivo imaging by protein modification with various sizes of polyethylene glycol (PEG) chain ('PEGylation'). Our experimental results demonstrate that modified contrast agents exhibit significant improvement of in vivo MR imaging and biocompatibilities including increases in relaxivities, protein solubility, and blood retention time and decreased immunogenicity.
Materials and methods

Protein engineering and PEGylation
The designed protein ProCA1 was expressed in E. coli BL21 (DE3) cell line. The purification procedures followed the protocols of GST-fusion protein purification using Glutathione Sepharose 4B beads (GE Healthcare). The GST-tag fused to proteins was cleaved on beads by the addition of thrombin (GE Healthcare). Methyl-PEO n -NHS esters, the deviant of PEG with different molecular weights of 0.3, 0.6, 2.4, 5, 12 and 20 kDa (Pierce and Jenkem, respectively) were selected to modify the designed protein. PEGylation was carried out in phosphate buffered saline buffer (pH 7.4) with a 1:5 ratio of protein and PEGs. Modified ProCA1s were further purified by FPLC and confirmed by MALDI-TOF mass spectrometric analysis.
Metal binding affinity and relaxivity measurement
The Gd 3+ -binding affinities with ProCA1 and ProCA1-PEG were investigated by competitive assay with the dye Fluo5N (a metal ion indicator, Invitrogen). The fluorescence spectra were collected on a fluorescence spectrophotometer (Photon Technology International, Inc.) with a 10 mm path length quartz cell at room temperature. The fluorescence intensity at 520 nm was normalized and the apparent constant was estimated by curve-fitting. The dissociation constant was calculated based on the K d measured in a previous report [17] . Spin-lattice relaxation time T 1 and spin-spin relaxation time T 2 of ProCA1s with various PEG sizes were determined on the selected magnetic field strength (0.47, 1.4, 3.0 and 9.4 T) at 37 °C in 10 mM Tris buffer, pH7.0. The relaxivities, r 1 and r 2, were calculated by the equation r i = 10 6 × (1/T i −1/T c )/ [Gd 3+ ], where T c is the relaxation time of the buffer.
Coordination water number determination
The number of water ligands coordinated to the Gd 3+ -ProCA1 complex was determined by measuring Tb 3+ luminescence decay in H 2 O or D 2 O. The Tb 3+ excited-state lifetime was measured using a fluorescence spectrophotometer (Photon Technology International, Inc.) with a 10 mm path length quartz cell at 22 °C. Following excitation at 265 nm with a XenoFlash lamp, Tb 3+ emission was monitored at 545 nm in both H 2 O and D 2 O systems. Luminescence decay lifetime was obtained by fitting the acquired data with a monoexponential decay function. A standard curve correlating the difference of rate constants obtained in H 2 O and D 2 O (Δk obs = k H2O − k D2O ) with water number (q) under our experimental conditions was established by using well-characterized chelators. The water numbers coordinated to the Tb 3+ -ProCA1s complexes were then obtained by fitting the acquired Δk obs value to the standard curve.
Immunogenicity and ELISA
Rabbits (n = 2) were intraperitoneally administrated Gd-ProCA1 and its PEGylated variants mixed with or without adjuvant according to the standard protocol. The rabbits were subjected to repeated immunizations over a 3-week interval. Blood samples were examined by ELISA and immunoblotting using polyclonal antibody PabCD2 as positive control and the pre-bleed as negative controls. In the ELISA, the secondary antibody, HRP, was conjugated and reacted with OPD for 5 min. The optical density at 490 nm was measured.
In vivo imaging
A Varian Inova 4.7 T/200 MHz/33cm horizontal/spectroscopy imaging system with a protocol approved by the Institutional Animal Care and Use Committee (IACUC) at Georgia State University was used in the in vivo imaging studies. During MR scan, the mice (20 -25 g, n = 4) were under anesthesia with 1.5% isoflurane gas mixture and then positioned and stabilized in the coil. The mice were kept warm with water bath during the scan. The mice were scanned before and after the administration of any contrast agents and kept in the same position. MR images of the whole body were acquired by T 1 -and T 2 -weighted fast spin echo sequences (TR(Repetition time) = 2 s, TE(Echo time) = 0.022 s, and ESP(Echo spacing) = 0.01 s) with field of view of 3 × 3 cm, matrix of 256 × 256, and slice thickness of 1 mm. The Gd-ProCA1-PEGs were prepared at a concentration of 1.2 mM in HEPES buffer, pH7.0. About 100 µL of the designed agent was injected into CD-1 mice via the tail vein each time. ImageJ (Rasbamd, W.S., NIH) was used to quantitatively analyze the MR images. The regions of interest were selected by circling the different parts of organs. Then the signal intensities were calculated and compared.
Blood retention time assay
The 153 Gd 3+ isotope dilution method was used. All agents were incubated with diluted 153 Gd 3+ at room temperature for 12 h and the free Gd 3+ was removed by Sephadex G25 desalting column. The CD-1 mice (20 -25g, n = 3) were executed at different time points after injection of about 100 µL agents at a concentration of 0.12 mM in HEPES buffer, pH7.0. The Gd 3+ content in blood and different organs was detected directly by measurement of 153 Gd 3+ radio activities.
Tumor cell targeting
The SKOV-3, which originates from human breast cancer, has a HER2expression level of about 10 6 /cell. The MBD-MB-231 is a HER2 negative cell line with a HER2 expression level of about 10 3 /cell. ProCA1-P2.4k and ProCA1-affi-P2.4k were incubated with the two kinds of cells at 37 °C for 1 h. Then the cells were washed at least 3 times, 5 min each, with Tris buffer containing glycine and methanol. The primary antibody was generated on rabbit by using ProCA1-affi as antigen. The secondary antibody was FITC conjugated (Invitrogen).
Results and discussion
Protein engineering and PEGylation
PEG is an FDA approved non-toxic, non-immunogenic, non-antigenic material which is highly soluble in water. PEGylation has been widely used as a modification method for improving the biomedical properties and pharmacokinetics of therapeutic proteins [18] [19] [20] [21] . Fig. 1A shows the modeled structure of the designed contrast agent ProCA1 with Gd 3+ binding site and the cartoon structure of the secondary and outer sphere water molecules associated with PEG chain.
Bacteria expressed and purified protein ProCA1 was PEGylated with Methyl-PEO n -NHS esters with different molecular weights of 0.3, 0.6, 2.4, 5, 12 and 20 kDa, respectively, and further purified by FPLC and confirmed by the MALDI-TOF mass spectrometric analysis (Supplementary data, Figs. S1, S2 and S3) with one to three PEG chains attached. First, we confirmed that PEGylated proteins maintain a native structure monitored by Trp fluorescence (Fig. 1B) . PEGylated ProCA1 exhibited similar disassociation constants for Gd 3+ with a 1 to 1 binding ratio to those of ProCA1 ( Fig. 2A and Table 1 ) [17] .
Metal binding affinity, relaxivity, and coordination water number measurement
Gd 3+ -binding affinities of PEGylated and native CA1.CD2 were determined by a competition titration with Fluo-5N applied as a Gd 3+ indicator in various chelate-metal buffer systems. The Gd 3+ -binding affinity of native ProCA1 was determined with an estimated apparent constant K app of 18 ± 3 µM ( Fig. 2A ). The dissociation constant (K d(Gd-ProCA1) = 3.5 × 10 −12 M) was calculated based on the K d measured in our previous report and the equation below [17] . The Gd 3+ -binding dissociation constants K d s of PEGylated ProCA1 variants were measured with the same method and summarized in Table  1 .
Next, we observed that the PEGylation modifications dramatically increased longitudinal and transverse relaxivities of the ProCA1 at different field strengths tested (0.47, 1.4, 3.0 and 9.4 T). The r 1 and r 2 values of ProCA1-PEG0.6k measured at 0.47 T were 39.5 mM −1 s −1 and 92.5 mM −1 s −1 , respectively, which is an increase of almost 66% and 110% compared with ProCA1. The r 1 and r 2 values of ProCA1-PEG2.4k increased by 100% and 125%. The r 1 and r 2 values of ProCA1-PEG12k were 83.8 mM −1 s −1 and 100.8 mM −1 s −1 , respectively, an increase of 252% and 130% from ProCA1. By comparison with Gd-DTPA, whose r 1 and r 2 values are less than 10 mM −1 s −1 at any magnetic field strength [22, 23] , the ProCA1 and PEGylated ProCA1 showed dramatically higher r 1 and r 2 values. ProCA1-PEG12k exhibited 19-fold higher r 1 and r 2 values compared with Gd-DTPA ( Fig. 3 and Table 1 ). PEGylated ProCA1 displayed relaxivities that were even higher than nanoparticle-based contrast agents, whose r 1 is 25.3 mM −1 s −1 at 1.4 T [24] . More interestingly, at high field strength of 9.4 T, ProCA1-PEG2.4k still exhibited great increase of relaxivity values r 1 and r 2 .
The coordination water numbers of both PEGylated and non-PEGylated ProCA1 were measured (Supplementary data, Fig. S4 ). Table 1 shows that ProCA1 had a hydration number of 2.4. PEGylation resulted in an increase of 0.2 -0.8 in hydration number. Subsequently, the hydrodynamic radii of modified ProCA1s were determined by a pulsefield-gradient diffusion NMR, which shows an increase from 16.9 ± 0.2, to 18.2 ± 1.1, 19.4 ± 0.55 and 40.2 ± 0.2 Å, with 0.6, 2.4 and 12 kDa PEG, respectively ( Table 1 and Fig. 2B ). Gd-DTPA generates an initial contrast in blood within 1 minute and circulation time and contrast last only 10 or less minutes [25] . After 20 minutes, no enhancement is seen (Fig.  S5) .
In vivo imaging
PEGylation increased the solubility of protein contrast agents in aqueous solutions 20-to 100-fold, most likely due to the strong hydrophilicity of the PEG chains. Significant increases in the solubility of contrast agents permit us to perform in vivo studies. Fig. 8 shows the T 1 -weighted fast spin-echo MR images of the mouse before (left) and 0.5 h after administration (right) of PEGylated Gd-ProCA1 (dose of 4.8 µmol kg −1 ) through tail vein injection. Significant contrast enhancements were observed in the kidney, liver, and blood vessels by comparison with pre-and post-contrast T 1 weighted images. The injection dose used was 20-fold lower than the Gd-DTPA dose typically used in clinics (0.1 mmol kg −1 ).
In vivo toxicity
The ProCA1 variants also exhibit low in vivo toxicity. Metal complexation is a key mediator or modifier of enzyme structure and function. Group IA metals Na + and K + play important and specific roles that assist function of biological macromolecules [26] . Ca 2+ plays a pivotal role in the physiology and biochemistry of organisms and the cell [27, 28] . As a result, it is essential to test the chemical properties. Selected metal ion concentrations (K + , Na + and Ca 2+ ) and enzymatic activity were measured from the collected blood of mice injected with ProCA1 and the PEG variants (Research Animal Diagnostic Laboratory, University of Missouri). The results ( Table 2) show that the metal ion concentrations of mice injected with ProCA1-PEGs are at the same level as those injected with saline. In addition, the level of liver enzyme alanine transaminase remains normal for mice administered ProCA1-PEGs compared to those injected with saline. However, kidney enzyme alkaline phosphatase (ALP) was present in lower levels for mice injected with ProCA1-PEGs than those injected with saline. In summary, we note no apparent in vivo toxicity of ProCA1 relative to the control group.
Blood retention and immunogenicity
The effect of PEGylation on blood retention of ProCA1 and its PEGylated variants in mice was examined by immunochemical assays (Fig. 5A ) and radioisotopic labelling using 153 Gd (Fig. 5C ). An increase of 7 and 4 times, respectively, for ProCA1.PEG2.4K and ProCA1.PEG0.6K was observed by comparison with non-PEGylated ProCA1 3 h after injection by immunochemical assay (Fig. 5A) . PEGylation significantly increased blood retention time compared to Gd-DTPA from under 3 minutes to over 3 hours [25] . The blood retention time also was increased 4 and 3 times, respectively, for ProCA1.PEG2.4K and ProCA1.PEG12K by comparison with native ProCA1 1 h after injection by 153 Gd labelling (Fig. 5C ). ProCA1-PEG2.4k exhibited the greatest increase in blood retention time.
Additionally, PEGylation was found to reduce the immunogenicity. Gd-ProCA1 and its PEGylated variants mixed with or without adjuvant were administered to rabbits intraperitoneally, and the rabbits were subjected to repeated immunizations over a 3-week interval. Blood samples were examined by ELISA and immunoblotting (Fig. 6 ) using polyclonal antibody PabCD2 as positive control and the pre-bleed as negative control. Although the addition of adjuvant indeed resulted in a strong immunoresponse, it was clear that without adjuvant, injection of ProCA1 did not lead to significant antibody production even after a double dose of immunization, suggesting that the immunogenicity of the ProCA1 is not strong, especially without addition of adjuvant. Additionally, this immunoresponse was dramatically reduced (~80%) by PEGylation with PEG2.4k. This data is consistent with observations for other protein drugs [20] .
We have also created a targeted contrast agent against the HER2 receptor over expressed in various cancer cells by fusion of a HER2 affibody [29] to the C-terminal of ProCA1 (denoted as ProCA1-affi). Fig. 7 shows that both ProCA1-affi and ProCA1-affi-PEG2.4k have similar capability to specifically bind to SKOV-3 ovarian cancer cells over-expressing HER2 (~3 × 10 6 /cell). On the other hand, they do not bind to MBD-MDA-231 cancer cells with low expression of HER2 (~2.7 × 10 3 /cell). Therefore, PEGylation does not impede the targeting capability and specificity of ProCA1 reagents, which is important for molecular imaging of biomarkers.
Conclusions
Different from the modest effect (15% increase) reported [11] for a small chelator as contrast agent, here we report the first observation of significantly enhanced relaxivities of protein contrast agents (up to 200%) by PEGylation. PEGylation also increases the blood retention up to 7 times by comparison with native ProCAs 3 h after injection. The results show that PEGylation improves the biomedical properties and pharmacokinetics of our designed protein contrast agents. Understanding the mechanisms for the increased relaxivity by PEGylation may allow us to identify new key factors contributing to the substantial improvement in relaxivities which is a major challenge in the field of molecular and biomarker targeted imaging. PEGylation may be a novel avenue to increasing relaxivity at high field strength to overcome the limitation of current, small Gd 3+ chelating contrast agents that suffer reduction of r 1 relaxivity under a high magnetic field (Fig. 2) . Such improvement can be important to the animal imaging and pre-clinical research under high or ultra-high field where there is an urgent need for molecular imaging probes and optimized contrast agents.
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Protein based contrast agent Table 1 . Relaxivity values r 1 (A) and r 2 (B) at field strengths 3.0 T(blue) and 9.4 T (red) of Gd-DTPA, ProCA1and its PEGylated variants. Relaxivity values r 1 (C) and r 2 (D) of Gd-DTPA (blue), ProCA1 (red), ProCA1-PEG0.6k (yellow), and ProCA1-PEG2.4k (green) at different field strengths. (A) ELISA of antibody produced in rabbit serum before (Pre) and weeks 3 (black) and 6 (grey) after intraperitoneal injection of ProCA1 and ProCA1-PEG2.4k mixed with adjuvant (ProCA1-Adjuvant) or with saline buffer (ProCA1). PabCD2 is the anti-serum from rabbits produced by CD2 (commercial source) as an antigen. PEGylation substantially reduced the immune response monitored by poly-antibodies. Antibody generation against the protein contrast agent (both PEGylated and native protein) in the rabbits was examined by Western Blotting. SDS-PAGE shows ProCA1-PEG2.4k (1), ProCA1-PEG0.6k (2) and ProCA1 (3) detected by anti-serum collected from immunoinoculated rabbits. PabCD2 was used as a positive control (E). The other antiserum was prepared from the blood collected after two subsequent injections of native protein ProCA1 mixed with adjuvant (B). ProCA1 in the absence of adjuvant (C). ProCA1-PEG2.4k mixed in absence of adjuvant (D). The results showe that addition of adjuvant induced stronger immune responses (B). PEGylation modifications of the protein dramatically reduced immune responses in the rabbits (D). Our results suggest that the immunogenecity of the protein contrast agent may not be very strong, especially without addition of adjuvant. Two types of cancer cell lines were stained by ProCA1-affi and ProCA1-affi-PEG2.4k, respectively. SKOV-3 over-expresses HER2 receptor, while MDA-MB-231 does not express HER2. ProCA1-affi or ProCA1-affi-PEG2.4k is shown in red and DAPI for nucleolus is shown in blue. Toxicity of designed protein contrast agents. 
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